Have any questions? 706-721-6582 or cts@augusta.edu
- FPA150-001: A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors
Clinical Trial
FPA150-001: A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors
The purpose of the study is to test a new investigational compound, called FPA150, (study drug), as single study drug treatment (alone) or in combination with pembrolizumab (study drug). FPA150, may eventually be used for the treatment of solid tumor cancers (not blood cancers).
Eligibility Criteria
- Male or female, aged 18 years or older Histologically confirmed solid tumors except primary central nervous system (CNS) tumors. Disease that is unresectable, locally advanced, or metastatic. Patients should be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition. Availability of archival tumor tissue and consent to providing archival tumor for retrospective biomarker analysis, or patient must undergo a fresh tumor biopsy during screening if archival tissue is not available (a biopsy is required for patients in the Phase 1a Dose Exploration portion). Prior radiotherapy must be completed at least 2 weeks before the first dose of study drug.
RESEARCH. INNOVATION. DISCOVERY.